PD-1/PD-L1 axis in lung cancer Journal Article
| Authors: | Santini, F. C.; Hellmann, M. D. |
| Article Title: | PD-1/PD-L1 axis in lung cancer |
| Abstract: | Cancer immunotherapies have revolutionized the treatment of non-small cell lung cancer. Yet, only a small subset of patients will benefit from PD-1 or PD-L1 blockade. PD-L1 tumor cell expression is the only approved biomarker at present. Tumor mutational burden and other emerging biomarkers should improve patient selection. Combination therapy approaches with chemotherapy or cytotoxic T-lymphocyte-associated protein 4 blockade may increase the proportion of patients who benefit from immunotherapy. Although use of immunotherapy in lung cancers with targetable oncogenes has not been particularly successful, the benefit of PD-(L)1 inhibitors in early-stage disease is emerging. This review briefly describes the evolution of the clinical development and future directions of PD-(L)1 blockade in patients with lung cancers. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. |
| Keywords: | review; advanced cancer; cancer combination chemotherapy; drug efficacy; monotherapy; antineoplastic agent; cancer immunotherapy; lung cancer; tumor marker; oncogene; immunotherapy; cytotoxic t lymphocyte; immunomodulating agent; programmed death 1 ligand 1; programmed death 1 receptor; nsclc; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); tumor immunogenicity; human; priority journal; anti-pd-1; anti-pd-l1 |
| Journal Title: | The Cancer Journal |
| Volume: | 24 |
| Issue: | 1 |
| ISSN: | 1528-9117 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2018-01-01 |
| Start Page: | 15 |
| End Page: | 19 |
| Language: | English |
| DOI: | 10.1097/ppo.0000000000000300 |
| PROVIDER: | scopus |
| PMCID: | PMC5784856 |
| PUBMED: | 29360723 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 March 2018 -- Source: Scopus |
